How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,999 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

301. Water vapor thermal therapy (WVTT) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)

Water vapor thermal therapy (WVTT) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

302. Alfuzosin in monotherapy and in combination therapy for the treatment of benign prostatic hyperplasia (BPH): efficacy and treatment profile

Alfuzosin in monotherapy and in combination therapy for the treatment of benign prostatic hyperplasia (BPH): efficacy and treatment profile Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

303. Long-Term Clinical Efficacy and Safety Profile of Transurethral Resection of Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. (Abstract)

Long-Term Clinical Efficacy and Safety Profile of Transurethral Resection of Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. To investigate the differences on clinical efficacy, complications, and safety profile between transurethral resection of the prostate (TURP) and bipolar plasmakinetic resection of the prostate (PKRP) for benign prostatic hyperplasia (BPH).Six hundred ninety patients of BPH were recruited from May 2008 to May 2011 and divided (...) into TURP group and PKRP group. The International Prostate Symptom Score (IPSS), quality of life score (QoL), postvoid residual urine (PVR), maximum flow rate (Qmax), complications, International Index of Erectile Function-5 (IIEF-5) questionnaire, and retrograde ejaculation were used for evaluation of clinical efficacy and safety and sexual function between the 2 groups.The intraoperative irrigation volume, postoperative irrigation volume, postoperative irrigation time, decrease in sodium

2017 Urology

304. Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia Full Text available with Trip Pro

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia The prostate specific antigen (PSA) test is widely used for early diagnosis of prostate cancer (PCa). However, its limited sensitivity has led to over-diagnosis and over-treatment of PCa. Glycosylation alteration is a common phenomenon in cancer development. Different PSA glycan subforms have been proposed as diagnostic markers to better differentiate PCa from (...) benign prostate hyperplasia (BPH). In this study, we purified PSA from expressed prostate secretions (EPS)-urine samples from 32 BPH and 30 PCa patients and provided detailed PSA glycan profiles in Chinese population. We found that most of the PSA glycans from EPS-urine were complex type biantennary glycans. We observed two major patterns in PSA glycan profiles. Overall there was no distinct separation of PSA glycan profiles between BPH and PCa patients. However, we detected a significant increase

2017 Oncotarget

305. Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population Full Text available with Trip Pro

Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population Lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH) are common conditions in middle-age or older men. The International Prostate Symptom Score (IPSS) is a useful and validated questionnaire to evaluate LUTS secondary to BPH. Van der Walt et al have developed an alternative (...) questionnaire named the Visual Prostate Symptom Score (VPSS) questionnaire. This study aimed to evaluate the relationship between the VPSS and IPSS in the evaluation of men with LUTSs due to BPH in an Indian population.This was a prospectively designed study conducted at Sri Sathya Sai Institute of Higher Medical Sciences, Prashanthigram (Anantapur, Andhra Pradesh, India). A total of 121 patients who presented to the urology outpatient department with LUTS due to BPH were enrolled in the study. Patients

2017 Prostate international

306. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]

[Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (...) ] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Paris: Haute Autorité de Santé (HAS). 2013

2013 Health Technology Assessment (HTA) Database.

307. Management of Benign Prostatic Hyperplasia (BPH)

Management of Benign Prostatic Hyperplasia (BPH) Management of Benign Prostatic Hyperplasia - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical (...) ) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Management of Benign Prostatic Hyperplasia Published 2010; Reviewed and Validity Confirmed 2014 Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. This guideline discusses proper evaluation and management, including interventional therapy, and treatment alternatives. [pdf] Panel Members Kevin T. McVary

2014 American Urological Association

308. [Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus]

[Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos. [Development of quality indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos. [Development of quality (...) indicators for laser treatment for benign prostatic hyperplasia. Expert consensus] Paz-Valiñas L, Queiro Verdes T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Paz-Valiñas L, Queiro Verdes T. Desarrollo de indicadores de calidad del tratamiento de la hiperplasia benigna de próstata mediante láser. Consenso de expertos.. [Development of quality

2013 Health Technology Assessment (HTA) Database.

309. Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: One-Year Results. (Abstract)

Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: One-Year Results. We sought to establish the safety and effectiveness of aquablation, a novel, image guided, robotic assisted, water jet tissue ablation technology, for the treatment of benign prostatic hyperplasia.We performed a prospective, single arm, multicenter trial at a total of 3 centers in Australia and New Zealand with 1-year followup. Participants were men 50 to 80 years old with moderate to severe lower (...) from 23.0 at baseline to 6.8 at 12 months (p <0.0001) and maximum urinary flow increased from 8.7 to 18.3 ml per second (p <0.0001). There were no important perioperative adverse events. No urinary incontinence developed and sexual function was preserved postoperatively.This phase II study provides early evidence to support the safety and effectiveness of aquablation for symptomatic benign prostatic hyperplasia.Copyright © 2017 American Urological Association Education and Research, Inc. Published

2017 Journal of Urology

310. Cone-beam CT findings during prostate artery embolization for benign prostatic hyperplasia-induced lower urinary tract symptoms: a case report Full Text available with Trip Pro

Cone-beam CT findings during prostate artery embolization for benign prostatic hyperplasia-induced lower urinary tract symptoms: a case report 29258481 2018 10 05 2018 11 13 1471-2490 17 1 2017 Dec 19 BMC urology BMC Urol Cone-beam CT findings during prostate artery embolization for benign prostatic hyperplasia-induced lower urinary tract symptoms: a case report. 120 10.1186/s12894-017-0311-6 Chen Chia-Bang CB Department of Radiology, Changhua Christian Hospital, No. 135, Nan-Hsiao Street (...) methods Embolization, Therapeutic methods Humans Lower Urinary Tract Symptoms diagnostic imaging therapy Male Prostate blood supply diagnostic imaging Prostatic Hyperplasia diagnostic imaging therapy Benign prostatic hyperplasia Cone-beam computed tomography Lower urinary tract symptoms Prostatic artery embolization 2017 01 19 2017 12 11 2017 12 21 6 0 2017 12 21 6 0 2018 10 6 6 0 epublish 29258481 10.1186/s12894-017-0311-6 10.1186/s12894-017-0311-6 PMC5738155 Tech Vasc Interv Radiol. 2012 Dec;15(4

2017 BMC urology

311. Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study Full Text available with Trip Pro

Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study Non-surgical minimally invasive treatments are greatly needed for patients with symptomatic benign prostatic hyperplasia (BPH), for whom medical treatment has failed and surgery is contraindicated. This study retrospectively evaluated the efficacy and safety of super-selective prostatic artery embolization (PAE) for BPH, relative (...) to transurethral resection of the prostate (TURP).To clinically evaluate the efficacy and safety of super-selective PAE for BPH, relative to TURP.From February 2012 to March 2015, patients with BPH underwent selective PAE (n = 17) or TURP (control group; n = 40). Prostate volume, maximum urinary flow rate (Qmax), International Prostate Symptoms Score (IPSS), and quality of life (QoL) score were evaluated at baseline and postoperative 3, 6, and 12 months. Complications were also recorded.All the procedures were

2017 Videosurgery and other Miniinvasive Techniques

312. Comparison of Safety, Efficacy and Cost Effectiveness of Photoselective Vaporization with Bipolar Vaporization of Prostate in Benign Prostatic Hyperplasia Full Text available with Trip Pro

Comparison of Safety, Efficacy and Cost Effectiveness of Photoselective Vaporization with Bipolar Vaporization of Prostate in Benign Prostatic Hyperplasia To compare bipolar vaporization of prostate (BPVP) with photoselective vaporization (PVP) of prostate in the surgical management of benign prostatic hyperplasia in terms of safety, efficacy and cost effectiveness.Data was analyzed retrospectively for patients who underwent either PVP or BPVP between August 2012 to July 2014 for prostate size (...) the groups.Both PVP and BPVP were safe and effective alternatives in men requiring surgery for benign prostatic hyperplasia including patients who were on anticoagulants. Additionally, BPVP has the advantage of being significantly cheaper and therefore it can be more useful in developing countries.

2017 Current urology

313. Association of Prostatic Volume and Carotid Intima-Media Thickness in Patients with Benign Prostatic Hyperplasia. (Abstract)

Association of Prostatic Volume and Carotid Intima-Media Thickness in Patients with Benign Prostatic Hyperplasia. To assess cardiovascular risk factors and carotid intima-media thickness in patients with benign prostatic hyperplasia.One hundred and twenty-three patients who were evaluated for the presence of benign prostatic hyperplasia with accompanying symptoms were included in the study. Patients were also examined by cardiology department to assess and measure cardiovascular risk factors (...) ). Linear regression analysis revealed that carotid intima-media thickness significantly associated with prostatic volume (beta coefficient: 0.628; confidence interval: 37.02-60.1; P = .001).We have demonstrated that prostatic tissue has significant association with carotid intima-media thickness in patients with benign prostatic hyperplasia.Copyright © 2017 Elsevier Inc. All rights reserved.

2017 Urology

314. Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia Full Text available with Trip Pro

Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia Estrogens act through interaction with 2 receptor subtypes, ER alpha (ERα) and ER beta (ERβ), in human prostate. The aim of the present study was to semiquantitatively assess the differential expression of ER subtypes in human benign prostatic hyperplasia (BPH) by use of immunocytochemistry (IHC) methods and to explore their relationship with various measures of BPH.A (...) total of 45 patients with BPH undergoing transurethral resection of the prostate and 22 patients with bladder cancer with normal prostate undergoing surveillance cystoscopy were studied as cases and controls, respectively. Quantitative immunolabeling of ER subtypes was scored by use of a semiquantitative scale. Also, correlations were assessed between ER levels in prostate and various measures of BPH.Overall, we found strong immunostaining for ERα in stroma and for ERβ in epithelium, respectively

2017 Investigative and clinical urology

315. Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia Full Text available with Trip Pro

Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia Autophagy is a conserved evolutionary process that allows cells to maintain macromolecular synthesis and energy homeostasis during starvation and stressful conditions. We prospectively evaluated the relationship between autophagy and prostatic inflammation in a series of transurethral prostatic resection samples. Inflammatory infiltrates were (...) defined according to the standardized classification of chronic prostatitis of the National Institute of Health. The inflammatory score (IS score) was calculated. High IS score was defined as ≥7. Each sample was stained for anti-LC3B and for anti-P62/SQSTM1 and scored. High p62 or LC3B percentage was defined as >25%, whereas low was defined as <25% of cells with dots. We analyzed 94 specimens. Overall, 18/94 (19%) showed no sign of prostatic inflammation, whereas 76/94 (81%) presented inflammatory

2017 Oncotarget

316. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia Full Text available with Trip Pro

Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia Prostate cancer (PCa) is one of the most common malignancies in men worldwide. Serum prostate specific antigen (PSA) level has been extensively used as a biomarker to detect PCa. However, PSA is not cancer-specific and various non-malignant conditions, including benign prostatic hyperplasia (BPH), can cause a rise in PSA blood levels, thus leading to many false positive results.In

2017 Metabolomics

317. Evaluation of biomarker canine-prostate specific arginine esterase (CPSE) for the diagnosis of benign prostatic hyperplasia Full Text available with Trip Pro

Evaluation of biomarker canine-prostate specific arginine esterase (CPSE) for the diagnosis of benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is the most common canine prostatic disorder. Although most or even all intact male dogs may develop BPH by 5-8 years of age, many show no clinical signs. Taking into account the non-specific character of clinical and ultrasonographic findings, a new diagnostic approach has recently been proposed based on the augmentation of blood canine (...) prostate-specific arginine esterase (CPSE) in hyperplasic dogs. The aim of the present study was to verify CPSE levels in negative controls and hyperplasic dogs, considering cytological findings as the reference method and taking into account the fact that controls were middle-aged intact dogs (median of 5.0 years), contrarily to previous studies carried out with very young control dogs.Significant differences of median CPSE levels were found between controls and hyperplasic dogs (29.1 versus 160.7 ng

2017 BMC veterinary research

318. Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia Full Text available with Trip Pro

Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia Prostatic carcinoma (PCa) derives from prostatic epithelial cells. However stromal microenvironment, associated with malignant epithelium, also plays a role in prostatic carcinogenesis. Alterations in prostatic stromal cells contribute to the loss of growth control in epithelial cells that lead to progression of PCa.To analyse the differences between Androgen Receptor (AR (...) ) expression in both epithelial and stromal cells in PCa and the surrounding benign prostatic hyperplasia (BPH) and to compare the results with tumour grade.Samples from 70 cases of radical prostatectomy specimens were used. The expression and intensity of the signal for AR was analysed in the epithelial and stromal cells of PCa and BPH, and the data was quantified using histological score (H-score).AR showed significantly lower expression in both epithelial and stromal cells of PCa compared to BPH. In PCa

2017 Open access Macedonian journal of medical sciences

319. Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells Full Text available with Trip Pro

Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells Benign prostatic hyperplasia (BPH) is a common disease in the male population, especially in elderly men. Vanillic acid (VA), a dihydroxybenzoic derivative used as a flavoring agent, is reported to have an anti-inflammatory effect. However, there are no reports of its effects on BPH to date. BPH was induced with a pre-4-week treatment of daily subcutaneous (...) injections of testosterone propionate (TP), and the normal control group received injections of ethanol with corn oil instead. Six weeks of further injections were done with (a) ethanol with corn oil, (b) TP only, (c) TP + finasteride, and (d) TP + VA. Finasteride was used as a positive control group. VA had protective effects on the TP-induced BPH. In the VA treatment group, the prostate weight was reduced, and the histological changes including the epithelial thickness and lumen area were restored like

2017 Oncotarget

320. Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression Full Text available with Trip Pro

Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression Aberrant restoration of AR activity is linked with prostate tumor growth, therapeutic failures and development of castrate-resistant prostate cancer. Understanding the processes leading to AR-reactivation should provide the foundation for novel avenues of drug discovery. A differential gene expression study was conducted using biopsies

2017 Scientific reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>